



PATENT

Attorney Docket No.: A-58624-2/RFT/RMK

Attorney File No.: 466673-33

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ZANETTI

Serial No. 10/667,299

Filing Date: September 18, 2003

For: *Treatment of HIV with Humic Acid*


Examiner: Not Yet Assigned

Group Art Unit: 1614

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including listed enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450:

Dated: March 16, 2004

Signed: 

Brent Yorckhara

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicant wishes to draw the attention of the U.S. Patent and Trademark Office to the references cited on the accompanying form PTO/SB/8A. Since this application is a continuation of the following related U.S. Application – Serial No. 08/310,675, filed September 22, 1994, copies of these references were provided either by Applicants or the Examiner. Therefore, in accordance with 37 C.F.R. § 1.98(d), no copies of these references are enclosed.

It is not believed that the foregoing reference discloses the invention as claimed. Nothing herein shall constitute an admission concerning the contents of the cited references, nor shall the inclusion of a reference herein be considered an admission that the reference constitutes prior art


Serial No. 10/667,299
Filing Date: September 18, 2003

against the invention claimed in the above-identified application. Submission of the present document shall not be construed as an admission that a search has been made or that better art does not exist.

As far as is known to the undersigned, this Information Disclosure Statement is being filed within three months of the filing date of a national application, within three months of the date of entry of the national state in an international application, or before the mailing date of a first Office Action on the merits as set forth in 37 C.F.R. § 1.97(b), and therefore no fee is required. While no further fee is believed to be due, if this belief is in error, the Commissioner is authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-2319 (Our Order No. 466673-33 (A-58624-2/RFT/RMK)).

Respectfully submitted,
DORSEY & WHITNEY LLP

Dated: 3/16/04
Customer Number: 32940
Dorsey & Whitney LLP
Intellectual Property Department
Four Embarcadero Center, Suite 3400
San Francisco, CA 94111-4187
Telephone: (415) 781-1989
Facsimile: (415) 398-3249

BY: 
Renee M. Kosslak, Reg. No. 47,717 for
Richard F. Trecartin, Reg. No. 31,801

Attachments : Form PTO/SB/8A, Substitute for form 1449
Return Postcard



Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/667,299	
			Filing Date	September 18, 2003	
			First Named Inventor	ZANETTI, Maurizio	
			Art Unit	1614	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	A-58624-2/RFT/RMK (466673-33)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ² Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B1	EP 0 537 430 A1	04-21-1993	Rütgerswerke AG		
	B2	EP 0 540 945 A1	05-12-1993	Torf Establishment		
	B3	WO 90/04412 A1	05-03-1990	Regents of the University of Minnesota		
	B4	WO 92/16216 A1	10-01-1992	Torf Establishment		
	B5	WO 94/18957 A1	09-01-1994	Levi, Ina		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
	C1	FLAIG, W., "Humic substances and associated small molecules from peats in balneology," <i>Sci. Total Environ.</i> 117-118:561-567 (1992).			
	C2	HILS, J., et al., "Inhibition of several strains of influenza virus type A and B by phenolic polymers," <i>Biomed. Biochim. Acta</i> 45(9):1173-1179 (1986).			
	C3	KLOECKING, R., et al., "Antiviral properties of humic acids," <i>Chem. Abstracts</i> , CAS Accession No. 77:57054q (1972).			
	C4	LOYA, S., et al., "Hexaprenoid Hydroquinones, Novel Inhibitors of the Reverse Transcriptase of Human Immunodeficiency Syndrome," <i>J. Nat. Prods.</i> 56(12):2120-2125 (Dec. 1993).			
	C5	RIEDE, U., et al., "Humates as antiviral agents," <i>Chem. Abstracts</i> , CAS Accession No. 118:247623n (1993).			
	C6	SCHNEIDER, J., et al., "HIV-Virostatic Effects of Humic Acids," <i>Off. J. Eur. Soc. Pathol.</i> , 190(3):245 (1994).			
	C7	SCHNEIDER, J., et al., "Inhibition of HIV-1 Infection by Synthetic Humates," <i>VIII Intl. Conf. AIDS/III STD World Cong.</i> , Abstract No. PuA 6152, p. 36, Amsterdam: NL (Jul. 19-24, 1992).			
	C8	THIEL, K.D., "Comparison of the <i>in vitro</i> effect of ammonium humate and of enzymically oxidized chlorogenic and caffeic acids against type 1 and type 2 human herpes-virus," <i>Chem. Abstracts</i> , CAS Abstract No. 94:150166p (1981).			
	C9	THIEL, K.D., et al., " <i>In vitro</i> Studies of the Antiviral Activity of Ammonium Humate Against Herpes simplex Virus Type 1 and Type 2," <i>Zbl. Bakt. Hyg., I. Abt. Orig. A</i> 239:304-321 (1977).			
	C10	WAGNER, H., "Topical agent for treatment of vesicular rash caused by herpes virus," <i>Chem. Abstracts</i> , CAS Accession No. 113:65270j (1990).			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2